Insilico Medicine reports 40% ORR for generative-AI-designed Pan-TEAD inhibitor ISM6331 in mesothelioma at ESMO 2026

Insilico Medicine reported a 40% objective response rate at 130 mg for its generative-AI-designed Pan-TEAD inhibitor ISM6331 in heavily pretreated mesothelioma, presented at ESMO 2026.

Detected & updated continuously · Source: Nebula